Antisense modulation of fibroblast growth factor receptor 4 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsSanjay Bhanot, Xing Xian Yu, Michael L. McCaleb
Life of this patent
Estimating the term…
Abstract
Provided herein are methods, compounds, and compositions for reducing expression of fibroblast growth factor receptor 4 (FGFR4) mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a metabolic disease, or a symptom thereof.
Claims35
A compound comprising a modified oligonucleotide consisting of 20 to 30 linked nucleosides having a nucleobase sequence comprising the sequence recited in SEQ ID NO:
- 16, 17, 45, 46, 70, 72, or 138.
2-11. (canceled)
(canceled)
(canceled)
25-27. (canceled)
29-40. (canceled)
47-91. (canceled)
A single-stranded oligonucleotide consisting of 20 linked nucleosides having a nucleobase sequence consisting of the sequence recited in SEQ ID NO:
- 16, wherein the oligonucleotide comprises
- a gap segment consisting of ten linked deoxynucleosides;
- a 5′ wing segment consisting of five linked nucleosides;
- and
- a 3′ wing segment consisting of five linked nucleosides;
- wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment;
- wherein each nucleoside of each wing segment comprises a 2′-O-methoxyethyl sugar;
- wherein each internucleoside linkage is a phosphorothioate linkage;
- and wherein each cytosine is a 5-methylcytosine.
Dependencies are inferred from the claim text.